IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ipca Laboratories posted strong Q3 FY26 results with standalone revenue from operations up 11% at Rs. 1,845.18 crores and consolidated revenue up 7% at Rs. 2,392.50 crores. Standalone net profit grew 13% to Rs. 303.45 crores while consolidated net profit jumped 31% to Rs. 326.27 crores. For nine months FY26, standalone net profit rose 22% to Rs. 870.23 crores and consolidated net profit rose 26% to Rs. 842.05 crores. EBITDA margins expanded notably, with standalone Q3 EBITDA margin at 26.09% (vs 24.25% in Q3 FY25) and consolidated at 22.15% (vs 19.87%). Indian formulations grew 12% and exports grew 13% during the quarter. The company also completed 100% acquisition of Unichem Laboratories Limited (Ireland) and incorporated a new wholly-owned subsidiary in Germany. Statutory auditor N V C & Associates LLP issued an unmodified limited review report.
Positive for shareholders: strong topline growth, healthy margin expansion, and solid profit growth signal operational momentum. The Unichem acquisition and German subsidiary expand the global footprint, though the European Commission fine provision remains a one-off watch item. Overall a healthy quarterly performance likely to support positive sentiment.